ReviewFrontiers in oncology2014
Strategies of dose escalation in the treatment of locally advanced non-small cell lung cancer: image guidance and beyond.
Review in Frontiers in oncology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Quantification of Lung Tumor Motion and Optimization of Treatment.Journal of biomedical physics & engineering · 2023Article
- Tumor-treating fields as a proton beam-sensitizer for glioblastoma therapy.American journal of cancer research · 2021Article
- Is tumor volume reduction during radiotherapy prognostic relevant in patients with stage III non-small cell lung cancer?Journal of cancer research and clinical oncology · 2018Article
- Prognostic value of tumor mutations in radically treated locally advanced non-small cell lung cancer patients.Oncotarget · 2017Article
- Use of Positron Emission Tomography/Computed Tomography in Radiation Treatment Planning for Lung Cancer.Molecular imaging and radionuclide therapy · 2016Article
- Cone-beam CT-guided radiotherapy in the management of lung cancer: Diagnostic and therapeutic value.Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2016Article
- Article
- The utility of positron emission tomography in the treatment planning of image-guided radiotherapy for non-small cell lung cancer.Frontiers in oncology · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Radiation dose in the setting of chemo-radiation for locally advanced non-small cell lung cancer (NSCLC) has been historically limited by the risk of normal tissue toxicity and this has been hypothesized to correlate with the poor results in regard to local tumor recurrences. Dose escalation, as a means to improve local control, with concurrent chemotherapy has been shown to be feasible with three-dimensional conformal radiotherapy in early phase studies with good clinical outcome. However, the potential superiority of moderate dose escalation to 74 Gy has not been shown in phase III randomized studies. In this review, the limitations in target volume definition in previous studies; and the factors that may be critical to safe dose escalation in the treatment of locally advanced NSCLC, such as respiratory motion management, image guidance, intensity modulation, FDG-positron emission tomography incorporation in the treatment planning process, and adaptive radiotherapy, are discussed. These factors, along with novel treatment approaches that have emerged in recent years, are proposed to warrant further investigation in future trials in a more comprehensive and integrated fashion.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.